GWM
CRBP icon

Geneos Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Geneos Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-120
Closed -$21K – 2264
2018
Q1 		$21K Buy
+120
New +$26.9K ﹤0.01% 1367

Other funds holding CRBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Geneos Wealth Management's CRBP Position: Q2 2018 in Review

Geneos Wealth Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2018, closing a stake of 120 shares — an estimated $21K sold.

Geneos Wealth Management first reported a position in CRBP in Q1 2018 and held it in 1 quarter. The position peaked at $21K in Q1 2018. 82 funds tracked by Wall St. Rank hold CRBP as of Q2 2018.

  • Geneos Wealth Management reported no remaining Corbus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Geneos Wealth Management sold 120 Corbus Pharmaceuticals shares in Q2 2018, an estimated $21K.
  • Geneos Wealth Management first reported a position in Corbus Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Geneos Wealth Management's Corbus Pharmaceuticals position peaked at $21K in Q1 2018.
  • 82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2018.

Based on Geneos Wealth Management's 13F filing for Q2 2018, filed 7 Sep 2021.